Richard D. Riley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard D. Riley has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Keith R. Abrams
Department of Statistics & Warwick Medical School (WMS), University of Warwick, Coventry, United Kingdom
5 shared publications - Paul Christopher Lambert
Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Dept Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
5 shared publications Alex J. Sutton
Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Princess Road West, Leicester LE1 6TP, United Kingdom
2 shared publications- Bridget Young
Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK
2 shared publications D Heney
22Department of Medical Education, University of Leicester, University Road, Leicester, UK
2 shared publicationsA J Sutton
11Department of Epidemiology and Public Health, University of Leicester, 22-28 Princess Road West, Leicester, LE1 6TP, UK
1 shared publication
Latest Publications
- 8 March 2006
- Published by Wiley in Statistics in Medicine
- Vol. 26 (1) , 78-97
An evaluation of bivariate random‐effects meta‐analysis for the joint synthesis of two correlated outcomes
Often multiple outcomes are of interest in each study identified by a systematic review, and in this situation a separate univariate meta‐analysis is usually applied to synthesize the evidence for each outcome independently; an alternative approach is a single multivariate meta‐analysis model that utilizes any correlation between outcomes and obtains all the pooled estimates jointly. Surprisingly, multivariate meta‐analysis is rarely considered in practice, so in this paper we illustrate the benefits and limitations of the approach to provide helpful insight for practitioners.We compare a bivariate random‐effects meta‐analysis (BRMA) to two independent univariate random‐effects meta‐analyses (URMA), and show how and why a BRMA is able to ‘borrow strength’ across outcomes. Then, on application to two examples in healthcare, we show: (i) given complete data for both outcomes in each study, BRMA is likely to produce individual pooled estimates with very similar standard errors to those from URMA; (ii) given some studies where one of the outcomes is missing at random, the ‘borrowing of strength’ is likely to allow BRMA to produce individual pooled estimates with noticeably smaller standard errors than those from URMA; (iii) for either complete data or missing data, BRMA will produce a more appropriate standard error of the pooled difference between outcomes as it incorporates their correlation, which is not possible using URMA; and (iv) despite its advantages, BRMA may often not be possible due to the difficulty in obtaining the within‐study correlations required to fit the model. Bivariate meta‐regression and further research priorities are also discussed. Copyright © 2006 John Wiley & Sons, Ltd.
- 8 March 2006
- Published by Wiley in Statistics in Medicine
- Vol. 26 (1) , 78-97
An evaluation of bivariate random‐effects meta‐analysis for the joint synthesis of two correlated outcomes
Often multiple outcomes are of interest in each study identified by a systematic review, and in this situation a separate univariate meta‐analysis is usually applied to synthesize the evidence for each outcome independently; an alternative approach is a single multivariate meta‐analysis model that utilizes any correlation between outcomes and obtains all the pooled estimates jointly. Surprisingly, multivariate meta‐analysis is rarely considered in practice, so in this paper we illustrate the benefits and limitations of the approach to provide helpful insight for practitioners.We compare a bivariate random‐effects meta‐analysis (BRMA) to two independent univariate random‐effects meta‐analyses (URMA), and show how and why a BRMA is able to ‘borrow strength’ across outcomes. Then, on application to two examples in healthcare, we show: (i) given complete data for both outcomes in each study, BRMA is likely to produce individual pooled estimates with very similar standard errors to those from URMA; (ii) given some studies where one of the outcomes is missing at random, the ‘borrowing of strength’ is likely to allow BRMA to produce individual pooled estimates with noticeably smaller standard errors than those from URMA; (iii) for either complete data or missing data, BRMA will produce a more appropriate standard error of the pooled difference between outcomes as it incorporates their correlation, which is not possible using URMA; and (iv) despite its advantages, BRMA may often not be possible due to the difficulty in obtaining the within‐study correlations required to fit the model. Bivariate meta‐regression and further research priorities are also discussed. Copyright © 2006 John Wiley & Sons, Ltd.
- 1 September 2004
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 57 (9) , 911-924
Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present
- 1 September 2004
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 57 (9) , 911-924
Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present
- 1 January 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (1) , 4-12
A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma
Purpose: The aim of this study was to conduct a systematic review, and where possible meta-analyses, of molecular and biological tumor markers described in neuroblastoma, and to establish an evidence-based perspective on their clinical value for the screening, diagnosis, prognosis, and monitoring of patients. Experimental Design: A well-defined, reproducible search strategy was used to identify the relevant literature from 1966 to February 2000. Results: A total of 428 papers studying the use of 195 different tumor markers in neuroblastoma were identified. Small sample sizes, poor statistical reporting, large heterogeneity across studies (e.g., in cutoff levels), and publication bias limited meta-analysis to the area of prognosis only; MYCN, chromosome 1p, DNA index, vanillylmandelic acid:homovanillic acid ratio, CD44, Trk-A, neuron-specific enolase, lactate dehydrogenase, ferritin, and multidrug resistance were all identified as potentially important prognostic tools. Conclusions: This systematic review forms a knowledge base of the tumor markers studied thus far in neuroblastoma, and has identified some of the most important prognostic markers, which should be considered in future research and treatment strategies. Importantly, the review has also highlighted some general problems across primary tumor marker studies, in particular poor and heterogeneous reporting. These need to be addressed to allow better clinical interpretation and enable more appropriate evidence-based reviews in the future. In particular, collaboration of cancer research groups is needed to enable bigger sample sizes, standardize methods of analysis and reporting, and facilitate the pooling of individual patient data.
- 1 January 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (1) , 4-12
A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma
Purpose: The aim of this study was to conduct a systematic review, and where possible meta-analyses, of molecular and biological tumor markers described in neuroblastoma, and to establish an evidence-based perspective on their clinical value for the screening, diagnosis, prognosis, and monitoring of patients. Experimental Design: A well-defined, reproducible search strategy was used to identify the relevant literature from 1966 to February 2000. Results: A total of 428 papers studying the use of 195 different tumor markers in neuroblastoma were identified. Small sample sizes, poor statistical reporting, large heterogeneity across studies (e.g., in cutoff levels), and publication bias limited meta-analysis to the area of prognosis only; MYCN, chromosome 1p, DNA index, vanillylmandelic acid:homovanillic acid ratio, CD44, Trk-A, neuron-specific enolase, lactate dehydrogenase, ferritin, and multidrug resistance were all identified as potentially important prognostic tools. Conclusions: This systematic review forms a knowledge base of the tumor markers studied thus far in neuroblastoma, and has identified some of the most important prognostic markers, which should be considered in future research and treatment strategies. Importantly, the review has also highlighted some general problems across primary tumor marker studies, in particular poor and heterogeneous reporting. These need to be addressed to allow better clinical interpretation and enable more appropriate evidence-based reviews in the future. In particular, collaboration of cancer research groups is needed to enable bigger sample sizes, standardize methods of analysis and reporting, and facilitate the pooling of individual patient data.
- Open Access
- 15 April 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (8) , 1191-1198
Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future
Prognostic markers help to stratify patients for treatment by identifying patients with different risks of outcome (e.g. recurrence of disease), and are important tools in the management of cancer and many other diseases. Systematic review and meta-analytical approaches to identifying the most valuable prognostic markers are needed because (sometimes conflicting) evidence relating to markers is often published across a number of studies. To investigate the practicality of this approach, an empirical investigation of a systematic review of tumour markers for neuroblastoma was performed; 260 studies of prognostic markers were identified, which considered 130 different markers. The reporting of these studies was often inadequate, in terms of both statistical analysis and presentation, and there was considerable heterogeneity for many important clinical/statistical factors. These problems restricted both the extraction of data and the meta-analysis of results from the primary studies, limiting feasibility of the evidence-based approach. Guidelines for reporting the results of primary prognostic marker studies in cancer, and other diseases, are given in order to facilitate both the interpretation of individual studies and the undertaking of systematic reviews, meta-analysis and, ultimately, evidence-based practice. General availability of full individual patient data is a necessary step forward and would overcome the majority of problems encountered, including poorly reported summary statistics and variability in cutoff level, outcome assessed and adjustment factors used. It would also limit the problem of reporting bias, although publication bias will remain a concern until studies are prospectively registered. Such changes in practice would help important evidence-based reviews to be conducted in order to establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care.
- 15 April 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (8) , 1191-1198
Open AccessReporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future
Prognostic markers help to stratify patients for treatment by identifying patients with different risks of outcome (e.g. recurrence of disease), and are important tools in the management of cancer and many other diseases. Systematic review and meta-analytical approaches to identifying the most valuable prognostic markers are needed because (sometimes conflicting) evidence relating to markers is often published across a number of studies. To investigate the practicality of this approach, an empirical investigation of a systematic review of tumour markers for neuroblastoma was performed; 260 studies of prognostic markers were identified, which considered 130 different markers. The reporting of these studies was often inadequate, in terms of both statistical analysis and presentation, and there was considerable heterogeneity for many important clinical/statistical factors. These problems restricted both the extraction of data and the meta-analysis of results from the primary studies, limiting feasibility of the evidence-based approach. Guidelines for reporting the results of primary prognostic marker studies in cancer, and other diseases, are given in order to facilitate both the interpretation of individual studies and the undertaking of systematic reviews, meta-analysis and, ultimately, evidence-based practice. General availability of full individual patient data is a necessary step forward and would overcome the majority of problems encountered, including poorly reported summary statistics and variability in cutoff level, outcome assessed and adjustment factors used. It would also limit the problem of reporting bias, although publication bias will remain a concern until studies are prospectively registered. Such changes in practice would help important evidence-based reviews to be conducted in order to establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care.
- 1 January 2003
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (1) , 19-30
A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family
- 1 January 2003
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (1) , 19-30
A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family